Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGONASDAQ:PRTCNASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00$0.00▼$0.00N/AN/AN/AN/APRTCPureTech Health$17.68-0.3%$17.68$13.30▼$28.39$429.94M1.154,695 shs900 shsSLNSilence Therapeutics$5.66+5.4%$4.39$1.97▼$22.47N/A1.41303,813 shs108,614 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%PRTCPureTech Health0.00%-9.82%+1.52%+1.91%-36.02%SLNSilence Therapeutics0.00%+1.25%+10.12%+58.99%-70.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APRTCPureTech Health1.8007 of 5 stars3.83.00.00.00.00.00.0SLNSilence Therapeutics2.8518 of 5 stars3.44.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/APRTCPureTech Health 3.50Strong Buy$45.00154.47% UpsideSLNSilence Therapeutics 2.71Moderate Buy$33.83497.76% UpsideCurrent Analyst Ratings BreakdownLatest ARIX, ERGO, SLN, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.006/13/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/APRTCPureTech Health$4.83M87.94$2.35 per share7.51$17.04 per share1.04SLNSilence Therapeutics$43.26MN/AN/AN/A$4.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/APRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)SLNSilence Therapeutics-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)Latest ARIX, ERGO, SLN, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/APRTCPureTech HealthN/A9.339.33SLNSilence TherapeuticsN/A8.818.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/APRTCPureTech Health0.04%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%PRTCPureTech Health5.30%SLNSilence Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionablePRTCPureTech Health10024.02 million22.75 millionNot OptionableSLNSilence Therapeutics100N/AN/ANot OptionableARIX, ERGO, SLN, and PRTC HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"June 16, 2025 | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan CapitalJune 16, 2025 | americanbankingnews.comSilence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC WainwrightJune 15, 2025 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)June 13, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan CapitalJune 13, 2025 | marketbeat.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comBrokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83June 10, 2025 | americanbankingnews.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from AnalystsJune 7, 2025 | marketbeat.comWall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a BetJune 6, 2025 | zacks.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)June 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DEJune 1, 2025 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)May 22, 2025 | marketbeat.comWall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeMay 21, 2025 | zacks.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARIX, ERGO, SLN, and PRTC Company DescriptionsEntia Biosciences OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.PureTech Health NASDAQ:PRTC$17.66 -0.07 (-0.39%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Silence Therapeutics NASDAQ:SLN$5.66 +0.29 (+5.40%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.61 -0.05 (-0.87%) As of 06/18/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
